Randomisierte, plazebokontrollierte klinische Doppelblindstudie zur Wirksamkeit und Verträglichkeit der oralen Therapie mit Methantheliniumbromid (Vagantin®) bei fokaler Hyperhidrose

Hund, Martina; Sinkgraven, Ronald; Rzany, Berthold

doi:10.1046/j.1439-0353.2004.04765.x

Cited by 52 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The idea of using an oral anticholinergic for the treatment of hyperhidrosis is not original, as it was first reported in 1951 (17). There are several clinical reports and case series on the use of oxybutynin to treat plantar sweating, but to the best of our knowledge, there have been no randomized clinical trials on the subject so far (16,18-20,26,29-32).…”

Section: Discussionmentioning

confidence: 99%

Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy

Costa¹,

Leão²,

Succi³

et al. 2014

Clinics

View full text Add to dashboard Cite

OBJECTIVE:Hyperhidrosis is a common disease, and thoracoscopic sympathectomy improves its symptoms in up to 95% of cases. Unfortunately, after surgery, plantar hyperhidrosis may remain in 50% of patients, and compensatory sweating may be observed in 70%. This clinical scenario remains a challenge. Our objective was to evaluate the effectiveness of oxybutynin in the treatment of persistent plantar hyperhidrosis and compensatory sweating and its effects on quality of life in women after thoracoscopic sympathectomy.METHOD:We conducted a prospective, randomized study to compare the effects of oxybutynin at 10 mg daily and placebo in women with persistent plantar hyperhidrosis. The assessment was performed using a quality-of-life questionnaire for hyperhidrosis and sweating measurement with a device for quantifying transepidermal water loss. Clinicaltrials.gov: NCT01328015.RESULTS:Sixteen patients were included in each group (placebo and oxybutynin). There were no significant differences between the groups prior to treatment. After oxybutynin treatment, there was a decrease in symptoms and clinical improvement based on the quality-of-life questionnaire (before treatment, 40.4 vs. after treatment, 17.5; p = 0.001). The placebo group showed modest improvement (p = 0.09). The outcomes of the transepidermal water loss measurements in the placebo group showed no differences (p = 0.95), whereas the oxybutynin group revealed a significant decrease (p = 0.001). The most common side effect was dry mouth (100% in the oxybutynin group vs. 43.8% in the placebo group; p = 0.001).CONCLUSION:Oxybutynin was effective in the treatment of persistent plantar hyperhidrosis, resulting in a better quality of life in women who had undergone thoracoscopic sympathectomy.

show abstract

Section: Discussionmentioning

confidence: 99%

Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy

Costa¹,

Leão²,

Succi³

et al. 2014

Clinics

View full text Add to dashboard Cite

show abstract

“…However long-term maintenance therapy is required to keep patients without symptoms [6,7]. Anticholinergic agents have substantial side effects such as dryness of mouth, constipation and blurring of vision [8,9]. Surgical therapeutic options like endoscopic sympathectomy are effective but have a main limitation in a great potential of side effect and in a high incidence of mild to severe compensatory hyperhidrosis [10].…”

Section: Introductionmentioning

confidence: 99%

Compared Evaluation of Botulinum Toxin A and a Cosmetic Antiperspirant in the Treatment of Focal Axillary Hyperhidrosis

Streker

Lübberding²,

Kerscher³

2013

JCDSA

View full text Add to dashboard Cite

Background: Primary focal hyperhidrosis can significantly reduce quality of life. Therefore a lot of treatment options in a range of conservative, physical and surgical techniques are available. Objective: To assess the efficacy of an antiperspirant containing aluminum chloride compared to a Botulinumtoxin A treatment for patients with primary focal hyperhidrosis. Methods and material: In this randomized, single-center, half-side trail, a clinical score was done by patients and physician to evaluate the severity of hyperhidrosis. Gravimetric tests were performed to gather the amount of sweat per unit of time. Furthermore the efficacy was determined using a four point questionnaire. Skin irritation was assessed by measuring pH value and transepidermal water loss. Results: A total of 22 patients were enrolled. Two weeks after baseline the hyperhidrosis level was significantly reduced (BTX-A: ﹣92.9%, AL: 66.7%). In addition both treatment options induced a significant reduction of sweat production (BTX-A: ﹣80.8%, AL: 68.8%). Please change in: Patients evaluated good resp, very good efficacy for both treatment options at day 28. pH value and TEWL never left physiological range. Conclusion: Both botulinum toxin A treatment and an antiperspirant containing aluminum chloride in the evaluated galenic formulation are an effective and safe treatment option for axillary focal hyperhidrosis.

show abstract

Focal Hyperhidrosis

Shams

Rzany²

2014

Evidence‐Based Dermatology

View full text Add to dashboard Cite

Randomisierte, plazebokontrollierte klinische Doppelblindstudie zur Wirksamkeit und Verträglichkeit der oralen Therapie mit Methantheliniumbromid (Vagantin®) bei fokaler Hyperhidrose

Cited by 52 publications

References 15 publications

Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy

Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy

Compared Evaluation of Botulinum Toxin A and a Cosmetic Antiperspirant in the Treatment of Focal Axillary Hyperhidrosis

Focal Hyperhidrosis

Contact Info

Product

Resources

About